Physician profile
Larry J Walker
NPI 1538140587
$1,671.21
in general payments reported to CMS, 2019-2025
21 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $90.42 · 2021: $110 · 2022: $155 · 2023: $227 · 2024: $283 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $258.28 | 2023-2025 | |
| Amgen INC. | $156.42 | 2019-2025 | Krystexxa, Parsabiv, Aranesp |
| Astrazeneca Pharmaceuticals Lp | $142.58 | 2019-2023 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $125.78 | 2020-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $121.60 | 2024 | |
| Ardelyx, INC. | $121.19 | 2024 | Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $120.23 | 2019-2023 | Velphoro |
| Medtronic, INC. | $116.23 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $109.29 | 2019-2021 | |
| Glaxosmithkline, LLC. | $85.83 | 2021-2023 | Benlysta, Jesduvroq |
| Daiichi Sankyo INC. | $47.63 | 2022 | |
| Mallinckrodt Enterprises LLC | $45.12 | 2019 | |
| Novo Nordisk INC | $35.66 | 2025 | Ozempic, Rybelsus |
| Nxstage Medical, INC. | $34.66 | 2022-2023 | Nxstage System One, Liberty Select Cycler |
| Opko Pharmaceuticals, LLC | $32.46 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $31.53 | 2019 | |
| Baxter Healthcare | $28.55 | 2020-2021 | |
| Akebia Therapeutics INC | $27.00 | 2024 | Auryxia |
| Mallinckrodt Hospital Products INC. | $15.44 | 2025 | Terlivaz |
| Cycle Pharmaceuticals INC | $13.24 | 2024 | Tiopronin |
| Travere Therapeutics, INC. | $2.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.